MedPath

Ephedrine

Generic Name
Ephedrine
Brand Names
Akovaz, Bronkaid, Corphedra, Emerphed, Primatene, Rezipres
Drug Type
Small Molecule
Chemical Formula
C10H15NO
CAS Number
299-42-3
Unique Ingredient Identifier
GN83C131XS
Background

Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with pseudoephedrine. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepinephrine from sympathetic neurons, inhibiting norepinephrine reuptake and displacing more norepinephrine from storage vesicles. Ephedrine is used for its vasoconstrictive, positive chronotropic, and positive inotropic effects. Ephedrine and phenylephrine are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists. Ephedrine was granted a type 7 FDA Approval on 29 April 2016.

Indication

Ephedrine intravenous injections are indicated to treat hypotension under anesthesia, ephedrine injections by multiple routes are indicated to treat allergic conditions such as bronchial asthma, ephedrine nasal spray is and OTC medication used as a decongestant.

Associated Conditions
Allergic Reaction, Bronchial Asthma, Common Cold, Cough, Depression, Fever, General Anesthesia Induced Hypotension, Headache, Joint Pain, Myasthenia Gravis, Narcolepsy, Nasal Congestion, Rhinorrhoea, Sore Throat, Dry cough
Associated Therapies
-

Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study

Phase 2
Completed
Conditions
Hypotension
Valve Surgery
Interventions
First Posted Date
2009-11-03
Last Posted Date
2020-09-02
Lead Sponsor
King Faisal University
Target Recruit Count
150
Registration Number
NCT01006863
Locations
🇪🇬

Mansoura University Hospitals, Mansoura, DK, Egypt

🇸🇦

King Fahd Hospital of the University, Dammam, Eastern, Saudi Arabia

Ephedrine for the Treatment of Congenital Myasthenia

Phase 1
Conditions
Myasthenic Syndromes, Congenital
First Posted Date
2007-10-10
Last Posted Date
2007-10-10
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
15
Registration Number
NCT00541216
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel

Phenylephrine in Spinal Anesthesia in Preeclamptic Patients

Not Applicable
Completed
Conditions
Preeclampsia
Hypotension
Interventions
First Posted Date
2007-04-09
Last Posted Date
2022-06-02
Lead Sponsor
Northwestern University
Target Recruit Count
110
Registration Number
NCT00458003
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat

Phase 2
Completed
Conditions
Obesity
First Posted Date
2006-09-19
Last Posted Date
2016-01-25
Lead Sponsor
Pennington Biomedical Research Center
Target Recruit Count
96
Registration Number
NCT00377975
Locations
🇺🇸

Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

© Copyright 2025. All Rights Reserved by MedPath